Consensus statement on the safety profile of topical calcineurin inhibitors.
Bieber
T
T
Cork
M
M
Ellis
C
C
Girolomoni
G
G
Groves
R
R
Langley
R
R
Luger
T
T
Meurer
M
M
Murrell
D
D
Orlow
S
S
Paller
A
A
de Prost
Y
Y
Puig
L
L
Ring
J
J
Saurat
J-H
JH
Schwarz
T
T
Shear
N
N
Stingl
G
G
Taieb
A
A
Thestrup-Pedersen
K
K
D000287:Administration, Topical; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D018570:Risk Assessment; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D065095:Calcineurin Inhibitors; C117268:pimecrolimus; D016559:Tacrolimus